Vividion Therapeutics Stock

vividion.comHealthcare / BioTech & PharmaFounded: 2013Funding to Date: $267.82MM

Vividion Therapeutics is a biotechnology company focused on transforming the future of human health through the creation of highly selective small molecule medicines that drug traditionally inaccessible targets.

Register To Buy and Sell Shares

For more details on financing and valuation for Vividion Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Vividion Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Vividion Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Trisha Millican
Chief Financial Officer
Benjamin Cravatt Ph.D
Scientific Co-Founder & Board Member
Diego Miralles MD
Chief Executive Officer & Board Member
Jin-Quan Yu Ph.D
Scientific Co-Founder
Fred Aslan MD
President & Chief Business Officer
Phil Baran Ph.D
Scientific Co-Founder

Board Members

Thomas Daniel MD
Richard Heyman Ph.D
Kristina Burow
ARCH Venture Partners
Thomas Woiwode Ph.D
Versant Venture Management
Jakob Loven Ph.D
Nextech Invest
Benjamin Cravatt Ph.D
Paul Schimmel Ph.D
John Clarke
Cardinal Partners
Diego Miralles MD

News Highlights

San Diego biotech Vividion raises $82 million
Company says it's leading a resurgence of traditional small-molecule drugs
Updated on: May 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.